BI 3006337

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BI 3006337, covering 2025-12-05 to 2026-01-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test How Well Men Tolerate Different Doses of BI 3006337 [Phase 1]